Peritonitis · chronic peritoneal dialysis patients
Oral or topical or intraperitoneal antibiotics showed no clear difference in peritonitis (number of patients with one or more episodes) compared with placebo/no treatment (low certainty).
1 finding from 1 review
Exit‐site/tunnel infection · chronic peritoneal dialysis patients
Oral or topical or intraperitoneal antibiotics showed no clear difference in exit‐site/tunnel infection (number of patients with one or more… compared with placebo/no treatment (low certainty).
1 finding from 1 review
Catheter removal or replacement · chronic peritoneal dialysis patients
Oral or topical or intraperitoneal antibiotics showed no clear difference in catheter removal or replacement (number of patients) compared with placebo/no treatment (low certainty).
1 finding from 1 review
Change in dry eye symptoms, measured using the OSDI score (ranging from 0 to 100 units, with a reduction in score indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in dry eye symptoms, measured using the OSDI score (ranging… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Change in ocular surface staining at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in ocular surface staining at 1‐month (with actual compared with placebo or no treatment (low certainty).
1 finding from 1 review
Aqueous tear production · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in Schirmer test (aqueous tear production, measured in mm/5… compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Tear film stability · people with dry eyea
1 finding from 1 review
Change in tear osmolarity (measured in mOsmol/L, with reductions in osmolarity indicating clinical improvement) at 1‐month (with actual · people with dry eyea
Oral long‐chain omega‐3 PUFAs (ie, EPA and DHA) showed no clear difference in change in tear osmolarity (measured in mOsmol/L, with reductions in… compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse event: gastrointestinal disorders at 1‐month (with actual · people with dry eyea
1 finding from 1 review
Major bleeding · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in major bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Minor bleeding · patients with active cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in minor bleeding compared with vitamin K antagonist secondary prophylaxis (low certainty).
1 finding from 1 review
Thrombocytopenia · patients with active cancer with venous thromboembolism
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Health related quality of life · patients with active cancer with venous thromboembolism
1 finding from 1 review
All‐cause mortality · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in all‐cause mortality compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
Recurrent VTE · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis may leads to lower recurrent VTE compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
Major bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in major bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
Major GI bleeding · patients with cancer with venous thromboembolism
Direct oral anticoagulant secondary prophylaxis showed no clear difference in major GI bleeding compared with low molecular weight heparin secondary prophylaxis (low certainty).
1 finding from 1 review
Major upper GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major upper GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
Major lower GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major lower GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review
Major non‐GI bleeding · patients with cancer with venous thromboembolism
It is very uncertain whether direct oral anticoagulant secondary prophylaxis changes major non‐GI bleeding compared with low molecular weight heparin secondary prophylaxis (very low certainty).
1 finding from 1 review